Ultragenyx Pharmaceutical
RARE
14.89
+0.43
+2.97%
Ultragenyx Pharmaceutical
US · RARE
#3012 by market cap
Listed 1970
14.89
+0.43
+2.97%
Live - 5344 symbols - heartbeat 247s ago
· 2026-10-08 08:38
Pre-market
14.84
-0.34%
After-hours
14.85
-0.27%
Overnight
14.89
0.00%
- Market cap
- 1.47B
- P/E (TTM)i
- -2.55
- P/Bi
- -5.04
- EPSi
- -5.83
- Div yieldi
- 0.00%
- 52W posi
- 8%
Reader sentiment
Are you bullish or bearish on RARE?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Weak
- Altman Z-Score is -3.86, below the 1.8 "distress zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +20.18% YoY
Margins
- Gross margin
- 83.80%
- Operating margin
- -79.49%
- Net margin
- -85.44%
Key ratios & quality
- Altman Z-Scorei
- -3.86
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 51.50M | 103.71M | 271.03M | 351.41M | 363.33M | 434.00M | 560.00M | 673.00M |
| Gross profit | 50.35M | 94.71M | 264.90M | 335.40M | 335.01M | 389.00M | 483.00M | 564.00M |
| Selling & admin expenses | 127.72M | 161.52M | 182.93M | 219.98M | 278.14M | 310.00M | 321.00M | 349.00M |
| Research & development | 294.00M | 357.36M | 412.08M | 497.15M | 705.79M | 648.00M | 698.00M | 750.00M |
| Operating profit | -371.37M | -424.17M | -330.12M | -381.74M | -648.92M | -569.00M | -536.00M | -535.00M |
| Pretax profit | -197.10M | -399.44M | -185.36M | -452.98M | -701.73M | -609.00M | -567.00M | -571.00M |
| Tax | 514.00K | 3.28M | 1.21M | 1.04M | 5.70M | -2.00M | 2.00M | 4.00M |
| Net profit | -197.61M | -402.73M | -186.57M | -454.03M | -707.42M | -607.00M | -569.00M | -575.00M |
| Basic EPS | -4 | -7 | -3 | -7 | -10 | -8 | -6 | -6 |
| Diluted EPS | -3.97 | -7.12 | -3.07 | -6.70 | -10.12 | -8.25 | -6.29 | -5.83 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 139.00M | 167.00M | 159.93M | 207.28M | 136.00M | 214.00M |
| Gross profit | 110.00M | 144.00M | 131.94M | 177.93M | 106.00M | 180.00M |
| Selling & admin expenses | 87.00M | 87.00M | 86.62M | 87.94M | 88.00M | 88.00M |
| Research & development | 166.00M | 165.00M | 216.21M | 203.28M | 187.00M | 167.00M |
| Operating profit | -143.00M | -108.00M | -170.89M | -113.28M | -169.00M | -75.00M |
| Pretax profit | -150.00M | -114.00M | -179.54M | -127.69M | -184.00M | -91.00M |
| Tax | 1.00M | 1.00M | 873.00K | 870.00K | 1.00M | 1.00M |
| Net profit | -151.00M | -115.00M | -180.41M | -128.56M | -185.00M | -92.00M |
| Basic EPS | -2 | -1 | -2 | -1 | -2 | -1 |
| Diluted EPS | -1.57 | -1.17 | -1.81 | -1.29 | -1.84 | -0.90 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 522.37M | 851.02M | 1.30B | 856.60M | 883.90M | 732.18M | 817.00M | 951.00M |
| Cash & ST investments | 459.71M | 755.23M | 1.20B | 740.20M | 747.76M | 577.21M | 610.00M | 680.00M |
| Inventory | 7.07M | 11.55M | 13.05M | 16.23M | 26.77M | 33.97M | 45.00M | 52.00M |
| Total assets | 719.56M | 1.14B | 1.76B | 1.52B | 1.55B | 1.49B | 1.50B | 1.53B |
| Total current liabilities | 74.73M | 103.30M | 189.61M | 181.37M | 261.21M | 280.44M | 344.00M | 384.00M |
| Short-term debt | -- | 7.24M | 8.98M | 11.07M | 11.78M | 12.60M | 10.00M | 12.00M |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 110,650,000.00 | 481,732,000.00 | 605,180,000.00 | 599,836,000.00 | 1,192,950,000.00 | 1,215,599,000.00 | 1,241,000,000.00 | 1,605,000,000.00 |
| Total equity | 608.91M | 653.76M | 1.15B | 922.56M | 352.49M | 275.41M | 262.00M | -73.00M |
| Retained earnings | -1.03B | -1.43B | -1.62B | -2.07B | -2.78B | -3.39B | -3.96B | -4.53B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 699.16M | 719.79M | 643.21M | 951.00M | 657.00M | 606.00M |
| Cash & ST investments | 494.44M | 477.39M | 425.25M | 680.00M | 413.00M | 292.00M |
| Inventory | 46.03M | 46.50M | 52.20M | 52.00M | 55.00M | 59.00M |
| Total assets | 1.31B | 1.31B | 1.19B | 1.53B | 1.30B | 1.26B |
| Total current liabilities | 291.67M | 293.24M | 340.02M | 384.00M | 325.00M | 351.00M |
| Short-term debt | 10.49M | 11.77M | 12.14M | 12.00M | -- | -- |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 1,160,681,000.00 | 1,147,979,000.00 | 1,174,286,000.00 | 1,605,000,000.00 | 1,525,000,000.00 | 1,548,000,000.00 |
| Total equity | 151.25M | 158.29M | 16.16M | -73.00M | -229.00M | -284.00M |
| Retained earnings | -4.11B | -4.22B | -4.40B | -4.53B | -4.72B | -4.81B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -290.57M | -345.38M | -132.22M | -338.70M | -380.47M | -475.00M | -414.00M | -466.00M |
| Depreciation & amortization | 19.54M | 8.54M | 12.26M | 13.24M | 18.22M | 26.00M | 36.00M | 35.00M |
| Free cash flow | -294.64M | -370.22M | -176.13M | -411.79M | -526.59M | -522.00M | -434.00M | -487.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 309.03M | 355.24M | 511.22M | 78.94M | 0 | 387.00M | 392.00M | 86.00M |
| Ending cash balance | 115.53M | 436.24M | 726.29M | 309.59M | 137.60M | 219.00M | 184.00M | 436.00M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -166.00M | -109.00M | -91.17M | -99.83M | -197.00M | -97.00M |
| Depreciation & amortization | 9.00M | 9.00M | 8.22M | 8.79M | 8.00M | 8.00M |
| Free cash flow | -182.00M | -112.00M | -92.23M | -100.77M | -203.00M | -98.00M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | -- | -- | -4.27M | 6.27M | -- | -- |
| Ending cash balance | 139.00M | 189.00M | 214.70M | 436.00M | 189.00M | 140.00M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -39.83 | -63.79 | -20.64 | -43.72 | -110.96 | -193.23 | -214.50 | -656.03 |
| ROA %i | -32.65 | -43.42 | -12.89 | -27.67 | -46.12 | -39.96 | -38.02 | -37.89 |
| ROIC %i | -41.23 | -61.58 | -17.68 | -40.05 | -101.17 | -161.51 | -178.51 | -433.78 |
| 5-year avg ROE %i | -63.45 | -52.74 | -48.73 | -47.69 | -55.79 | -86.49 | -116.64 | -243.94 |
| EBIT margin %i | -721.18 | -384.05 | -56.11 | -120.53 | -181.30 | -124.92 | -90.06 | -75.63 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 6.99 | 8.24 | 6.83 | 4.72 | 3.38 | 2.61 | 2.38 | 2.48 |
| Quick ratioi | 6.32 | 7.63 | 6.46 | 4.24 | 3.02 | 2.32 | 2.13 | 2.18 |
| Debt / assetsi | 0.00 | 3.26 | 2.74 | 2.76 | 2.04 | 2.90 | 2.66 | 2.35 |
| LT debt / equityi | -- | 4.55 | 3.40 | 3.35 | 5.62 | 11.10 | 11.76 | -- |
| Interest coveragei | -- | -350.93 | -4.57 | -14.40 | -15.31 | -8.22 | -8.00 | -8.21 |
| Revenue CAGR (3Y) %i | -- | 820.44 | 369.91 | 89.68 | 51.88 | 16.99 | 16.80 | 22.81 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -386.33 | -182.60 | -325.76 | -656.03 | -- | -- |
| ROA %i | -41.97 | -36.44 | -42.50 | -37.89 | -46.70 | -45.60 |
| ROIC %i | -290.60 | -155.70 | -262.38 | -433.78 | -- | -- |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -82.21 | -77.16 | -82.25 | -75.63 | -80.00 | -70.43 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 2.40 | 2.45 | 1.89 | 2.48 | 2.02 | 1.73 |
| Quick ratioi | 2.03 | 2.05 | 1.58 | 2.18 | 1.64 | 1.40 |
| Debt / assetsi | 2.92 | 2.78 | 2.84 | 2.35 | -- | -- |
| LT debt / equityi | 19.26 | 16.22 | 236.83 | -- | -- | -- |
| Interest coveragei | -7.89 | -7.90 | -8.93 | -8.21 | -7.77 | -6.56 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Research, development and commercialization of its products100.00%
Quote time 2026-10-08 08:38:31 · For reference only, not investment advice and not tailored to your situation.